cancerBiology180x110

Unum’s Antibody-Directed T Cells: Differentiated from CAR T-Cell and T Cell Receptor Reprogramming

Unum Therapeutics is a new immunotherapy biotechnology company in which Fidelity Biosciences, Atlas Ventures and Sanofi invested $12 MM in a Series A (first venture round) of investment. Continue reading

cancerBiology180x110

Lentiviral Vectors for Gene Transfection in CAR T-cell Therapy

Novartis entered into a $90 MM deal with Oxford Biomedica for use of its lentiviral vectors with its CAR (chimeric antigen receptor) modified T-cell product, CTL019, being developed with researchers at UPENN. Continue reading

seal

IND for Clinical Studies of dCellVax Breast Cancer Immune Therapy Filed – Intelligent and Rational Gene Silencing Approach for Cancer

Regen Biopharma recently filed an IND (Investigational New Drug Application) with the FDA to permit the initiation of Phase 1 clinical trials of its dCellVax treatment for advanced breast cancer. Continue reading

cancerBiology180x110

The Texas 2 Step Approach to Cancer Cyberwarfare via Exosomes

Multi-modality (surgery, chemo, radiation) therapy and combination chemotherapy (e.g, CHOP and ABVD) have long been the mainstays of treating cancer. So, we should not be surprised to read about the discovery made by scientists at Rice University and MD Anderson regarding a two-step approach involving radiation and immunotherapy. Continue reading

cancerBiology180x110

Chop Protein Suppresses the Immune Response in Cancer

The Chop protein, not to be confused with the CHOP chemotherapy regimen for lymphoma (Cyclophosphamide, Hydro doxorubicin – Adriamycin, Oncovin – vincristine, and Prednisone), is a multifunctional transcription factor. This 29 kda protein that is produced following unfolded protein stress in the endoplasmic reticulum, which then triggers apoptosis. Continue reading

cancerBiology180x110

Selectively Targeting Metabolism in Mitochondria In Cancer Cells

An experimental drug, CPI-613, was shown to be safe and induce several responses in a Phase I study of patients with advanced refractory hematologic malignancies. The drug targets mitochondrial enzymes of cancer cells and is not harmful to normal cells at therapeutic doses. Continue reading

seal

Attacking Brain Cancer in its Hypoxic Environment

As tumors grow and become unresponsive to external cellular signals, the level of oxygen in the masses decreases; mutated cells, those with malfunctioning p53, grow and thrive greater than 0.2 mm from the blood supply. Continue reading

cancerBiology180x110

Obesity soon to replace tobacco as the number one preventable / treatable cause of cancer

“Obesity is on its way to replacing tobacco as the number one preventable / modifiable cause of cancer,” says Clifford Hudis, MD, the 2013-2014 President of the American Society of Clinical Oncology. Indeed, obese post-menopausal women have up to twice the risk of developing breast cancer as do their normal weight counterparts. Continue reading